NCT02042196View on ClinicalTrials.gov

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

May 2, 2016

Study Completion Date

May 2, 2016

Conditions
MenopauseAging
Interventions
DRUG

KUVAN

KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.

DRUG

Placebo

Placebo pills designed to match the dissolvable KUVAN pills

DRUG

Cetrotide

Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.

DRUG

Climara

0.075mg/d transdermal patch will be placed on skin.

DRUG

Placebo transdermal patch

Inactive transdermal patch

Trial Locations (1)

80045

University of Colorado Denver, Aurora

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Colorado, Denver

OTHER

NCT02042196 - Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women | Biotech Hunter | Biotech Hunter